Combination of Docetaxel and Gemcitabine Ineffective in Metastatic Eccrine Porocarcinoma: A Case Report

Basit Öğe Kaydı
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorHacioglu, Muhammet Bekir
dc.contributor.authorKostek, Osman
dc.contributor.authorErdogan, Bulent
dc.contributor.authorTastekin, Ebru
dc.contributor.authorKodaz, Cagnur Elpen
dc.contributor.authorCicin, Irfan
dc.date.accessioned2024-06-12T10:50:46Z
dc.date.available2024-06-12T10:50:46Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractMalignant eccrine porocarcinoma is a very rare tumor and the etiology is not known. Treatment is surgical removal of the tumor. The benefit of chemotherapy and radiotherapy is unclear. A 49-year-old male patient presented with the complaint of left inguinal swelling. Ultrasonography examination revealed 5x4 cm inguinal lymphadenopathy. The inguinal lymph nodes were excised. Pathology report indicated eccrine porocarcinoma. The patient was treated with cisplatin 40 mg/m(2) week as well as concurrent radiotherapy for 5 weeks. After 6 weeks of dual therapy, liver metastases were detected. KRAS, NRAS, and BRAF tests were negative. Gemcitabine was administered at a dose of 1000 mg/m(2) on days 1 and 8 every 21 days, and docetaxel was administered at a dose of 75 mg/m(2) on day 8, every 21 days. There was progression after 2 cycles of chemotherapy. The patient lived 7 months. In this case, use of synchronous cisplatin and radiotherapy as adjuvant treatment could not prevent tumor metastasis. The combination chemotherapy of docetaxel and gemcitabine applied after metastatic disease development was ineffective.en_US
dc.identifier.doi10.14744/ejmo.2017.43153
dc.identifier.endpage40en_US
dc.identifier.issn2587-196X
dc.identifier.issue1en_US
dc.identifier.startpage38en_US
dc.identifier.urihttps://doi.org/10.14744/ejmo.2017.43153
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18108
dc.identifier.volume1en_US
dc.identifier.wosWOS:000604198100008en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofEurasian Journal Of Medicine And Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdjuvant Cisplatinen_US
dc.subjectBRAFen_US
dc.subjectDocetaxelen_US
dc.subjectEccrine Porocarcinomaen_US
dc.subjectGemcitabineen_US
dc.subjectKRASen_US
dc.subjectNRASen_US
dc.titleCombination of Docetaxel and Gemcitabine Ineffective in Metastatic Eccrine Porocarcinoma: A Case Reporten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu